Discovery of Dual Orexin Receptor Antagonists (DORAs) for the Treatment of Insomnia

Current Topics in Medicinal Chemistry

Volumn 11, Issue 6, 2011, Pages 696-725

  Coleman, Paul J ^a   Cox, Christopher D ^a   Roecker, Anthony J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Brain penetration; Diazepane; G protein coupled receptor; Insomnia; Neuropeptide; Orexin; Sleep

Indexed keywords

ALMOREXANT; JNJ 1037049; OREXIN; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; OREXIN RECEPTOR BLOCKING AGENT; RECEPTOR BLOCKING AGENT; SB 649868; UNCLASSIFIED DRUG;

DRUG ACTIVITY; DRUG PENETRATION; DRUG POTENCY; DRUG STRUCTURE; HUMAN; INSOMNIA; NONHUMAN; RECEPTOR BLOCKING; REVIEW; SLEEP; WAKEFULNESS;

EID: 79952946685     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026611109060696     Document Type: Review

References (59)

1. de Lecea, L.; Kilduff, T. S.; Peyron, C.; Gao, X.; Foye, P.E.; Danielson, P. E.; Fukuhara, C.; Battenberg, E.L.; Gautvik, V. T.; Bartlett, F.S.; Frankel, W. N.; van den Pol, A. N.; Bloom, F. E.; Gautvik, K. M.; Sutcliffe, J. G. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. USA, 1998, 95, 322-327.
2. Sakurai, T.; Amemiya, A.; Ishii, M.; Matsuzaki, I.; Chemelli, R.M.; Tanaka, H.; Williams, S.C.; Ri-chardson, J. A.; Kozlowski, G. P.; Wilson, S.; Arch, J. R. S.; Buc-kingham, R. E.; Haynes, A. C.; Carr, S. A.; Annan, R. S.; McNulty, D. E.; Liu, W.-S.; Terrett, J.A.; Elshourbagy, N.A.; Bergsma, D. J.; Yanagisawa, M. Orexins and orexin receptors: a family of hypot-halamic neuropeptides and G protein-coupled receptors that regula-te feeding behavior. Cell, 1998, 92, 573-585.
3. Peyron, C.; Tighe, D. K.; vand den Pol, A. N.; de Lecea, L.; Heller, H. C.; Sutcliffe, J. G.; Kilduff, T. S. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci., 1998, 18, 9996-10015.
4. Nunez, A.; Rodrigo-Angulo, M. L.; de Andres, I.; Garzon, M. Hypocretin/orexin neuropeptides: participation in the control of sleep-wakefulness cycle and energy homeostasis. Curr. Neuropharmacol., 2009, 7(1), 50-59.
5. Nishino, S. Clinical and neurobiological aspects of narcolepsy. Sleep Med., 2007, 8 (4), 373-399.
6. Mochizuki, T.; Crocker, A.; McCormack, S.; Yanagisawa, M.; Sakurai, T.; Scammell, T. E. Behavioral state instability in orexin knock-out mice. J. Neurosci., 2004, 24(28), 6291-300.
7. Chemelli, R.M.; Willie, J.T.; Sinton, C. M.; Elmquist, J.K.; Scammell, T.; Lee, C.; Richardson, J.A.; Williams, S. C.; Xiong, Y.; Kisanuki, Y.; Fitch, T. E.; Nakazato, M.; Hammer, R. E.; Saper, C. B.; Yana-gisawa, M. Narcolepsy in orexin knockout mice: molecular genet-ics of sleep regulation. Cell, 1999, 98(4), 437-451.
8. Foutz, A. S.; Mitler, M. M.; Cavalli-Sforza, L. L.; Dement, W. C. Genetic factors in canine narcolepsy. Sleep, 1979, 1(4), 413-421.
9. Riehl, J.; Nishino, S.; Cederberg, R.; Dement, W. C.; Mignot, E. Development of cataplexy in genetically narcoleptic dobermans. Exp. Neurol., 1998, 152(2), 292-302.
10. Peyron, C.; Faraco, J.; Rogers, W.; Ripley, B.; Overeem, S.; Char-nay, Y.; Nevsimalova, S.; Aldrich, M.; Reynolds, D.; Albin, R.; Li, R.; Hungs, M.; Pedrazzoli, M.; Padigaru, M.; Kucherlapati, M.; Fan, J.; Maki, R.; Lammers, G. J.; Bouras, C.; Kucherlapati, R.; Ni-shino, S.; Mignot, E. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narco-leptic brains. Nat. Med., 2000, 6(9), 991-997.
11. Brisbare-Roch, C.; Dingemanse, J.; Koberstein, R.; Hoever, P.; Aissaoui, H.; Flores, S.; Mueller, C.; Nayler, O.; van Gerven, J.; de Haas, S.; Hess, P.; Qiu, C.; Buchmann, S.; Scherz, M.; Weller, T.; Fischli, W.; Clozel, M.; Jenck, F. Promotion of sleep by targeting the orexin system in rats, dogs, and humans. Nat. Med., 2007, 13, 150-155.
12. Boss, C.; Brisbare-Roch, C.; Jenck, F.; Aissaoui, H.; Ko-berstein, R.; Sifferlen, T.; Weller, T. Orexin Receptor antagonism: A new principle in neuroscience. Chimia, 2008, 62, 974-979.
13. Roecker, A. J.; Coleman, P. J. Orexin receptor antagonists: medici-nal chemistry and therapeutic potential. Curr. Top. Med. Chem., 2008,8(11), 977-987.
14. Sakurai, T.; Moriguchi, T.; Furuya, K.; Kajiwara, N.; Nakamura, T.; Yanagasawa, M.; Goto, K. Structure and function of human prepro-orexin gene. J. Biol. Chem., 1999, 274, 17771-17776.
15. Zhu, Y.; Miwa, Y.; Yamanaka, A.; Yada, T.; Shibahara, M.; Abe, Y.; Sakurai, T.; Goto, K. Orexin receptor type-1 couples exclu-sively to pertussis toxin-insensitive G-proteins, while orexin recep-tor type-2 couples to both pertussis toxin-sensitive and -insensitive G-proteins. J. Pharmacol. Sci., 2003, 92(3), 259-266.
16. Nishino, S.; Honda, K.; Fujiki, N.; Wurts, S. W.; Sakurai, E.; Kato, M.; Watanabe, T.; Mignot, E.; Yanai, K. The role of histamine in a hypocretin (orexin)-deficient sleep disorder, narcolepsy. Internatio-nal Congress Series 2001, 1224(Histamine Research in the New Millennium), 247-251.
17. Vittoz, N. M.; Berridge, C.W. Hypocretin/orexin selectively in-creases dopamine efflux within the prefrontal cortex: Involvement of the ventral tegmental area. Neuropsychopharmacology, 2006, 31(2), 384-395.
18. Bernard, R.; Lydic, R.; Baghdoyan, H. A. Hypocretin-1 causes G protein activation and increases ACh release in rat pons. Eur. J. Neurosci., 2003, 18 (7), 1775-1785.
19. Prud'homme, M. J.; Lacroix, M. C.; Badonnel, K.; Gougis, S.; Baly, C.; Salesse, R.; Caillol, M. Nutritional status modulates be-havioral and olfactory bulb Fos responses to isoamyl acetate or food odour in rats: roles of orexins and leptin. Neuroscience, 2009, 162(4), 1287-1298.
20. Kim, J.; Nakajima, K.; Oomura, Y.; Wayner, M. J.; Sasaki, K. Orexin-A and ghrelin depolarize the same pedunculopontine teg-mental neurons in rats: An in vitro study. Peptides, 2009, 30(7), 1328-1335.
21. Burdakov, D.; Jensen, L. T.; Alexopoulos, H.; Williams, R. H.; Fearon, I. M.; O'Kelly, I.; Gerasimenko, O.; Fugger, Lars.; Verk-hratsky, Alexei. Tandem-pore K+ channels mediate inhibition of orexin neurons by glucose. Neuron, 2006, 50(5), 711-722.
22. Coleman, P. J.; Renger, J. J.; Orexin Receptor Antagonists: A re-view of promising compounds patented since 2006. Expert Opin. Ther. Pat., 2010, 20(3),307-324
23. Di Fabio, R.; Gerrard, P.; Porter, R.; Stemp, G.; Nash, D.; Branch, C.; Massagrande, M.; Poffe, A.; Piccoli, L.; Braggio, S.; Ratti, E. Bis-amido piperidine derivatives as in vitro and in vivo potent dual orexin receptor antagonists. Abstracts of Papers, 238th ACS Na-tional Meeting, Washington, DC, United States, August 16-20, 2009.
24. Smart, D.; Sabido-David, C.; Brough, S. J.; Jewitt, F.; Johns, A.; Porter, R. A.: Jerman, J. C.; SB-334867-A: the first selective orexin-1 receptor antagonist. Br. J. Pharmacol., 2001, 132, 1179-1182.
25. Dugovic, C.; Shelton, J.E.; Aluisio, L.E.; Fraser, I.C.; Jiang, X.; Sutton, S.W.; Bonaventure, P.; Yun, S.; Li, X.; Lord, B.; Dvorak, C. A.; Carruthers, N. I.; Lovenberg, T.W. Blockade of orexin-1 re-ceptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. J. Pharmacol. Exp. Ther., 2009, 330(1), 142-151.
26. Mobarakeh, J. I.; Takahashi, K.; Sakurada, S.; Nishino, S.; Wata-nabe, H.; Kato, M.; Yanai, K. Enhanced antinociception by intrac-erebroventricularly and intrathecally-administered orexin A and B (hypocretin-1 and -2) in mice. Peptides (New York, NY, United States) 2005, 26(5), 767-777.
27. Suzuki, M.; Beuckmann, C. T.; Shikata, K.; Ogura, H.; Sawai, T. Orexin-A (hypocretin-1) is possibly involved in generation of anxi-ety-like behavior. Brain Res., 2005, 1044(1), 116-121.
28. Feng, P.; Vurbic, D.; Wu, Z.; Hu, Y.; Strohl, K. P. Changes in brain orexin levels in a rat model of depression induced by neonatal ad-ministration of clomipramine. J. Psychopharmacol., 2008, 22(7), 784-791.
29. Harris, G. C.; Wimmer, M.; Aston-Jones, G. A role for lateral hypothalamic orexin neurons in reward seeking. Nature, 2005, 437, 556-559.
30. de Lecea, L.; Jones, B. E.; Boutrel, B.; Borgland, S. L.; Nishino, S.; Bubser, M.; DiLeone, R. Addiction and arousal: al-ternative roles of hypothalamic peptides. J. Neurosci., 2006, 26, 10372-10375.
31. Winrow, C. J.; Tanis, K. Q.; Reiss, D. R.; Rigby, A. M.; Uslaner, J. M.; Uebele, V. N.; Doran, S. M.; Fox, S.V.; Gar-son, S. L.; Gotter, A. L.; Levine, D. M.; Roecker, A. J.; Coleman, P. J.; Koblan, K. S.; Renger, J. J. Orexin receptor antagonism pre-vents transcriptional and behavioral plasticity resulting from stimu-lant exposure. Neuropharmacology, 2010, 58(1),185-194.
32. Whitman, D.B.; Cox, C. D.; Breslin, M. J.; Brashear, K.M.; Schreier, J. D.; Bogusky, M. J.; Bednar, R. A.; Lemaire, W.; Bruno, J.G.; Hartman, G. D.; Reiss, D. R.; Harrell, C. M.; Kraus, R. L.; Li, Y.; Garson, S.L.; Doran, S. D.; Prueksaritanont, T.; Li, C.; Winrow, C. J.; Koblan, K. S.; Renger, J. J.; Coleman, P. J. Discov-ery of potent, CNS-penetrant orexin receptor antagonist based on N,N-disubstituted 1,4-diazepane scaffold that promotes sleep in rats. Chem. Med. Chem., 2009, 4, 1069-1074.
33. Hirose, M.; Egashira, S.; Goto, Y. Takashi, H.; Ohtake, N.; Iwaasa, H.; Hata, M.; Fukami, T.; Kanatani, A.; Yamada, K. N-acyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline: The first orexin-2 recep-tor selective non-peptidic antagonist. Bioorg. Med. Chem. Lett., 2003,13, 4497-4499.
34. Breslin, M. J.; Cox, Christopher D.; Whitman, David B. Diazaspi-rodecane orexin receptor antagonists. PCT Int. Appl., WO 2007025069, 2007.
35. Bergman, J.M.; Coleman, P.J.; Roecker, A.J. Preparation of indole compounds containing an oxazole moiety as orexin receptor an-tagonists. PCT Int. Appl., WO 2007061763A1. 2007.
36. Peterson, L.A. Electrophilic intermediates produced by bioacti-vation of furan. Drug Met. Rev., 2006, 38, 615-626.
37. Zhang, K. E.; Naue, J. A.; Arison, B.; Vyas, K. P. Microsomal metabolism of the 5-lipoxygenase inhibitor L-739,010: Evidence for furan bioac-tivation. Chem. Res. Toxicol., 1996, 9, 547-554.
38. Bergman, J. M.; Roecker, A. J.; Mercer, S. P.; Bednar, R. A.; Reiss, D. R.; Ransom, R. W.; Harrell, C. M.; Pettibone, D. J.; Le-maire, W.; Murphy, K. L.; Li, C.; Preuksaritanont, T.; Winrow, C. J.; Renger, J. J.; Koblan, K. S.; Hartman, G. D.; Coleman, P. J. Proline bis-amides as potent dual orexin receptor antagonists. Bioorg. Med. Chem. Lett., 2008, 18, 1425-1430.
39. Bergman, J.M.; Coleman, P. J.; Cox, C. D.; Hartman, G.D.; Lindsley, C.; Mercer, S. P.; Roecker, A. J.; Whitman, D. B. Preparation of proline bis-amide orexin receptor antagonists. PCT Int., WO2006127550A1, 2006.
40. Sigler, R. E.; Dominick, M. A.; McGuire, E. J. Subacute toxic-ity of a halogenated pyrrole hydroxymethylglutaryl-coenzyme A reductase inhibitor in Wistar rats. Toxicol. Pathol., 1992, 20, 595-602.
41. Cheeke, P. R. Toxicity and metabolism of pyrrolizidine al-kaloids. J. Amin. Sci., 1988, 66, 2343-2350.
42. Compound 5-14 demonstrated an IC50 = 2.5 M against CYP 3A4 and an EC50 = 1.9 M inducing hPXR. These CYP-related issue were representative of the proline bis-amide series of orexin an-tagonists.
43. Gaillard, Pascale; Johnson, Christopher Norbert; Novelli, Riccardo; Porter, Roderick Alan; Stemp, Geoffrey; Thewlis, Kevin Michael. Preparation of N-aroyl cyclic amines as orexin receptor antago-nists. PCT Int. Appl., WO 2002089800 A2. 2002.
44. Coleman, P. J.; Schreier, J. Preparation of amidopropoxyphenyl compounds as orexin receptor antagonists for treating neurological and psychiatric disorders. PCT Int. Appl., WO 2006110626. 2006, A1.
45. He, H.; Lyons, K. A.; Shen, X.; Yao, Z.; Bleasby, K.; Chan, G.; Hafey, M.; Li, X.; Xu, S.; Salituro, G. M.; Cohen, L. H.; Tang, W. Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure. Xenobiotica, 2009,39(9), 687-693.
46. Lin, J. H. CSF as a surrogate for assessing CNS exposure: an in-dustrial perspective. Curr. Drug Metabol., 2008, 9(1), 46-59.
47. Coleman, P. J.; Schreier, J.D. Amidoethyl alkylamino orexin recep-tor antagonists. PCT Int. Appl., WO 2009011775A1. 2009.
48. Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem., 2002, 45(12), 2615-2623.
49. Brashear, K. M.; Coleman, P. J.; Cox, C. D.; Smith, A. M.; Whit-man, D. B. Diazepane orexin receptor antagonists. PCT Int. Appl., WO 2007126935. 2007,
50. Cox, C. D.; Breslin, M. J.; Coleman, P. J. Substituted diazepane orexin receptor antagonists. PCT Int. Appl., WO 2008008518. 2008.
51. Bergman, J. M.; Breslin, M. J.; Coleman, P. J.; Cox, C. D.; Mercer, S. P.; Roecker, A. J. Substituted diazepane orexin re-ceptor antagonists. US Patent Appl., US 2008 132490. 2008.
52. Bergman, J. M.; Coleman, P. J.; Cox, C. D.; Roecker, A. J. Substi-tuted diazepane orexin receptor antagonists. PCT Int. Appl., WO 2009058238.2009,
53. Cox, C. D.; McGaughey, G. B.; Bogusky, M. J.; Whitman, D. B.; Ball, R. G.; Winrow, C. J.; Renger, J. J.; Coleman, P. J. Conforma-tional analysis of N,N-disubstituted-1,4-diazepane orexin receptor antagonists and implications for receptor binding. Bioorg. Med. Chem. Lett., 2009, 19, 2997-3001.
54. Coleman, P. J.; Schreier, J. D.; McGaughey, G. B.; Bogusky, M. J.; Cox, C. D.; Hartman, G. D.; Ball, R. G.; Harrell, C. M.; Reiss, D. R.; Prueksaritanont, T.; Winrow, C. J.; Renger, J. J. Design and synthesis of conformationally constrained N.N-disubstituted 1,4-diazepanes as potent orexin receptor antagonists. Bioorg. Med. Chem. Lett., 2010, 20, 2311-2315.
55. Coleman, P. J.; Cox, Christopher D.; McGaughey, G. B.; Ro-ecker, A. J.; Schreier, J. D. Preparation of bridged diazepane com-pounds as orexin receptor antagonists. PCT Int. Appl., WO 2008008517. 2008.
56. Coleman, P. J.; Schreier, J. D.; Roecker, A. J.; Mercer, S. P.; McGaughey, G. B.; Cox, C. D; Hartman, G. D.; Harrell, C. M.; Reiss, D. R.; Garson, S. L.; Anderson, W. B.; Prueksaritanont, T.; Winrow, C. J.; Renger, J. J. Discovery of 3,9-diazabicyclo[4.2.1] nonanes as potent orexin receptor antagonists with sleep-promoting activity in the rat. Bioorg. Med. Chem. Lett., 2010, doi:10.1016/ j.bmcl.2010.05.047
57. Three atom bridges containing an oxygen atom were also made and found to be potent DORAs; see: Cox, Christopher D.; Whitman, David B. Oxo bridged diazepane orexin receptor antagonists. PCT Int. Appl., 2008 WO 2008143856.
58. Coleman, P. J.; Cox, C. D.; Breslin, M. J.; Schreier, J. D.; Ro-ecker, A. J.; Whitman, D. B.; Mercer, S. P.; Bergman, J. P.; Brashear, K. M.; McGaughey, G. G.; Bednar, R. A.; Lemaire, W.; Doran, S. M.; Fox, S. V.; Garson, S. L.; Harrell, C. M.; Kraus, R. L.; Murphy, K.; Reiss, D. R.; Cui, D.; Li, C.; Prueksaritanont, T.; Roller, S.; Tang, C.; Stevens, J.; Tannenbaum, P.; Young, S. D.; Koblan, K. S.; Winrow, C. J.; Hartman, G. D.; Renger, J. J. Dis-covery of MK-4305: A novel orexin receptor antagonist for the treatment of insomnia. Abstracts of Papers, 239th ACS National Meeting, San Francisco, CA, United States, March 21-25, 2010 (2010), MEDI-37.
59. Cox, C. D.; Breslin, M. J.; Whitman, D. B.; Schreier, J. D.; McGaughey, G. B.; Bogusky, M. J; Roecker, A. J.; Mercer, S. P.; Bednar, R. A.; Lemaire, W.; Bruno, J. G.; Reiss, D. R.; Harrell, C. M.; Murphy, K. L.; Garson, S L.; Doran, S. M.; Prueksaritanont, T.; Anderson, W. B.; Tang, C.; Roller, S.; Cabalu, T. D.; Cui, D.; Hartman, G. D.; Young, S. D.; Koblan, K. S.; Win-row, C. J.; Renger, J. J.; Coleman, P. J. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl] methanone (MK-4305) for the treatment of insomnia. J. Med. Chem., 2010, 53(14),5320-5332.